image

The best stocks to buy since 1993

Latest issue now available

Immupharma

February 2018

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • IMM
  • Price:
  • 135.5p
 I made Immupharma (IMM; 135.5p) one of my NAPS in the January issue. I know I could be a hostage to fortune highlighting it ahead of the phase III trial results for its potential blockbuster, Lupuzor, a treatment for systemic lupus erythematosus (SLE) but I am hopeful of favourable clinical data.   If you have bought, I want to press home that there is also the potential for a trial failure and although the drug has other potential uses in treating rheumatoid arthritis, Crohn's disease and asthma, for my NAP purposes I need good results to propel the shares this year and so this is really a single shot at the goal. Crucially ahead of the trial results, the company has hedged its bets with a placing to raise &pou ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X

LIMITED PERIOD OFFER!

SUBSCRIBE TODAY AND SAVE £30 WITH OFFER CODE 30OFFSCSW

To access our archive of articles and to receive current issues you need to subscribe